Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Chao

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Cancer Genetics|October 14, 2017
Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research NetworkThomas Slavin, Susan L Neuhausen, Christina Rybak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, et al.
Breast Cancer Research : BCR|August 31, 2017
Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancerYuan Yuan, Nilesh Vora, Can-Lan Sun, et al.
JAMA Oncology|September 30, 2021
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical TrialDaneng Li, Can-Lan Sun, Heeyoung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or AnusAlexa B Schrock, Dean Pavlick, Samuel J Klempner, et al.
Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Cancer Genetics|October 14, 2017
Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research NetworkThomas Slavin, Susan L Neuhausen, Christina Rybak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, et al.
Breast Cancer Research : BCR|August 31, 2017
Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancerYuan Yuan, Nilesh Vora, Can-Lan Sun, et al.
JAMA Oncology|September 30, 2021
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical TrialDaneng Li, Can-Lan Sun, Heeyoung Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or AnusAlexa B Schrock, Dean Pavlick, Samuel J Klempner, et al.
Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Pageof 12